PCM
MURA

Prelude Capital Management’s Mural Oncology MURA Stock Holding History

Prelude Capital Management’s Portfolio MURA Stock Details MURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-136,934
Closed -$338K – 1298
2025
Q2 		$338K Buy
+136,934
New +$323K 0.03% 567

Other funds holding MURA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Prelude Capital Management's MURA Position: Q3 2025 in Review

Prelude Capital Management sold out of Mural Oncology (MURA) in Q3 2025, closing a stake of 136,934 shares — an estimated $338K sold.

Prelude Capital Management first reported a position in MURA in Q2 2025 and held it in 1 quarter. The position peaked at $338K in Q2 2025. 61 funds tracked by Wall St. Rank hold MURA as of Q3 2025.

  • Prelude Capital Management reported no remaining Mural Oncology position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 136,934 Mural Oncology shares in Q3 2025, an estimated $338K.
  • Prelude Capital Management first reported a position in Mural Oncology in Q2 2025 and held it in 1 quarter.
  • Prelude Capital Management's Mural Oncology position peaked at $338K in Q2 2025.
  • 61 funds tracked by Wall St. Rank held Mural Oncology as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.